Crossmark

Co-administration of H-ferritin-doxorubicin and Trastuzumab in neoadjuvant setting improves efficacy and prevents cardiotoxicity in HER2 + murine breast cancer model

Crossref DOI link: https://doi.org/10.1038/s41598-020-68205-w

Published Online: 2020-07-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Andreata, F. https://orcid.org/0000-0002-5710-3671
Bonizzi, A.

Sevieri, M.

Truffi, M.

Monieri, M.

Sitia, L.

Silva, F.

Sorrentino, L.

Allevi, R.

Zerbi, P.

Marchini, B.

Longhi, E.

Ottria, R. https://orcid.org/0000-0003-3379-0582
Casati, S. https://orcid.org/0000-0002-5049-7321
Vanna, R. https://orcid.org/0000-0001-6218-8393
Morasso, C.

Bellini, M.

Prosperi, D.

Corsi, F.

Mazzucchelli, S.
Funding

Funding for this research was provided by:

Fondazione Cariplo (2016-0919)
License Information

Text and Data Mining valid from 2020-07-10

Version of Record valid from 2020-07-10
More Information

Article History

Received: 25 February 2019

Accepted: 22 June 2020

First Online: 10 July 2020

Competing interests

: The authors declare no competing interests.

Document is current

Any future updates will be listed below